Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andro Targeted By FDA In Coordination With Capitol Hill Action

This article was originally published in The Tan Sheet

Executive Summary

FDA is aiming to remove androstenedione supplements from the market by classifying the substance as a new dietary ingredient that has not been the subject of a safety notification to the agency, as required by the Dietary Supplement Health & Education Act

You may also be interested in...



DMAA Warnings Shed Light On FDA NDI Enforcement

FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.

DMAA Warnings Shed Light On FDA NDI Enforcement

FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.

FDA Warning Draws Solid Line Between Steroid Products And Supplements

FDA's enforcement approach toward a firm warned about marketing synthetic steroids as dietary supplements represents a more watertight legal strategy than the agency has used in similar scenarios

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS096572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel